AU2001280368A1 - Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy - Google Patents
Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapyInfo
- Publication number
- AU2001280368A1 AU2001280368A1 AU2001280368A AU8036801A AU2001280368A1 AU 2001280368 A1 AU2001280368 A1 AU 2001280368A1 AU 2001280368 A AU2001280368 A AU 2001280368A AU 8036801 A AU8036801 A AU 8036801A AU 2001280368 A1 AU2001280368 A1 AU 2001280368A1
- Authority
- AU
- Australia
- Prior art keywords
- antibodies
- immunotherapy
- stimulating
- cells
- production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0002835A SE0002835D0 (en) | 2000-08-07 | 2000-08-07 | Method and kit for production of monoclonal antibodies |
SE0002835 | 2000-08-07 | ||
PCT/SE2001/001714 WO2002012535A1 (en) | 2000-08-07 | 2001-08-07 | Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001280368A1 true AU2001280368A1 (en) | 2002-02-18 |
Family
ID=20280635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001280368A Abandoned AU2001280368A1 (en) | 2000-08-07 | 2001-08-07 | Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy |
Country Status (4)
Country | Link |
---|---|
US (1) | US20040005321A1 (en) |
AU (1) | AU2001280368A1 (en) |
SE (1) | SE0002835D0 (en) |
WO (1) | WO2002012535A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004053139A1 (en) * | 2002-12-10 | 2004-06-24 | Apollo Life Sciences Limited | A method of antibody production |
US8815248B2 (en) | 2005-06-09 | 2014-08-26 | Gal Markel | Modulation of immunity and CEACAM1 activity |
CA2760385C (en) * | 2009-04-30 | 2021-04-20 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Anti ceacam1 antibodies and methods of using same |
DE102010024636B4 (en) | 2010-06-22 | 2024-04-18 | Universität Duisburg-Essen | Antibodies, especially for diagnostics |
WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
JP2015525781A (en) * | 2012-07-31 | 2015-09-07 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | Modulating the immune response |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
MD20160130A2 (en) | 2014-04-27 | 2017-04-30 | Ccam Biotherapeutics Ltd. | Humanized antibodies against CEACAM1 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA919299B (en) * | 1990-11-26 | 1992-08-26 | Akzo Nv | Method for the production of antibodies |
DE69925909T2 (en) * | 1998-04-15 | 2006-05-11 | Brigham & Women's Hospital, Inc., Boston | T-cell inhibiting receptor compositions and their use |
CA2383562A1 (en) * | 1999-08-26 | 2001-03-01 | Keith M. Skubitz | Peptides capable of modulating the function of cd66 (ceacam) family members |
-
2000
- 2000-08-07 SE SE0002835A patent/SE0002835D0/en unknown
-
2001
- 2001-08-07 US US10/344,036 patent/US20040005321A1/en not_active Abandoned
- 2001-08-07 WO PCT/SE2001/001714 patent/WO2002012535A1/en active Application Filing
- 2001-08-07 AU AU2001280368A patent/AU2001280368A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002012535A1 (en) | 2002-02-14 |
SE0002835D0 (en) | 2000-08-07 |
US20040005321A1 (en) | 2004-01-08 |
WO2002012535B1 (en) | 2002-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2940044B8 (en) | Anti-tnf alpha antibodies for use in therapy | |
EP1392361A4 (en) | Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 | |
WO2002030986A3 (en) | HUMANIZED ANTI-LT-β-R ANTIBODIES | |
IL205511A0 (en) | Methods and compositions for the production of monoclonal antibodies | |
AU2003257850A1 (en) | ANTIBODY SPECIFIC TO CENTRAL Tau-PROTEIN | |
AU2003264009A1 (en) | Humanized rabbit antibodies | |
IL156618A0 (en) | Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same | |
AU2002340167A1 (en) | Anti-hla-dr antibodies and the methods of using thereof | |
AU4935000A (en) | Antibodies | |
AU2003209059A1 (en) | Human monoclonal antibodies against membrane proteins | |
AU2001256325A1 (en) | Human and humanized fap-alpha-specific antibodies | |
AU5441000A (en) | Human monoclonal antibody | |
HK1048650A1 (en) | Methods for enhancing the production of cytokines in cell cultur e | |
HK1055750A1 (en) | Monoclonal antibodies to the human ldl receptor, their production and use | |
AU2001280368A1 (en) | Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy | |
AU2002251821A1 (en) | Nicotine immunogens and antibodies and uses thereof | |
AU2003276844A1 (en) | Formulations of modified antibodies and methods of making the same | |
AU2003210054A1 (en) | Anti-rank monoclonal antibodies and pharmaceutical composition containing the same | |
AU2002953238A0 (en) | In vitro immunization | |
EP1621555A4 (en) | Immunogen, composition for immunological use, and method of producing antibody using the same | |
AU2452301A (en) | Protein methylarginine-specific antibodies | |
EP1380646A4 (en) | Acetyllysine-recognizing monoclonal antibody and process for producing the same | |
AU2003282241A1 (en) | Antibodies for in vitro use | |
AU2002249221A1 (en) | Use of casb7439 (ash2) in the immunotherapy of breast cancer | |
AU2002321440A1 (en) | Expression of modified antibodies in avian cells |